期刊
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
卷 138, 期 43, 页码 14206-14209出版社
AMER CHEMICAL SOC
DOI: 10.1021/jacs.6b08957
关键词
-
资金
- Marie Curie Actions [600388]
- European Research Council [340055]
- Spanish MINECO [CTQ2014-59808R, SAF2013-41943-R, CTQ2015-70698-R, CTQ2013-49317-EXP]
- Generalitat of Catalonia [2014-SGR-480, AGAUR 2014 052, AGAUR 2014 054]
- Xunta de Galicia [GRC2013-041]
- Medcom Advance S.A.
- ICREA Funding Source: Custom
Blood-based biomarkers (liquid biopsy) offer extremely valuable tools for the noninvasive diagnosis and monitoring of tumors. The protein c-MYC, a transcription factor that has been shown to be deregulated in up to 70% of human cancers, can be used as a robust proteomic signature for cancer. Herein, we developed a rapid, highly specific, and sensitive surface-enhanced Raman scattering (SERS) assay for the quantification of c-MYC in real blood samples. The sensing scheme relies on the use of specifically designed hybrid plasmonic materials and their bioderivatization with a selective peptidic receptor modified with a SERS transducer. Peptide/c-MYC recognition events translate into measurable alterations of the SERS spectra associated with a molecular reorientation of the transducer, in agreement with the surface selection rules. The efficiency of the sensor is demonstrated in cellular lines, healthy donors and a cancer patient.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据